CION Ameerpet
CAR T-cell therapy is one of the most advanced — and most expensive — options for certain relapsed lymphomas. This guide gives honest, indicative price ranges, explains what the package includes, and shows how CION coordinates the pathway and confirms whether it is genuinely right for you.
If you have been told CAR T-cell therapy might be an option, the first question is usually about cost — and the honest answer is that it is expensive. In India, an Indian-manufactured CAR T-cell product is typically in the region of ₹30–45 lakh for the cell product alone, with a total treatment package commonly reaching ₹40–60 lakh once hospital admission, the preparatory chemotherapy step and intensive monitoring are added. Imported products cost considerably more. These are indicative ranges only; every quote depends on the exact product, the treating centre and how long you stay in hospital.
CAR-T is a one-time cellular therapy: your own immune T-cells are collected, re-engineered in a specialised laboratory to recognise a marker such as CD19 on lymphoma cells, then infused back to attack the cancer. It is used for selected relapsed or refractory B-cell lymphomas — not as a first treatment, and not for everyone. For most people, standard, far less costly treatment works well.
This page explains the car-t price for lymphoma stage by stage, how it compares with other options, what insurance and government schemes may cover, and how CION coordinates the pathway. For the wider picture, see lymphoma treatment cost in Hyderabad and the main lymphoma hub.
India's first indigenously developed CAR T-cell therapy was granted market approval by the Central Drugs Standard Control Organisation (CDSCO) in October 2023. Its arrival brought the cost of the cell product down to roughly a tenth of imported equivalents — one reason CAR-T is now discussed more often in Indian lymphoma care, though it remains a high-cost option reserved for selected relapsed or refractory cases. (Source: CDSCO approval, 2023, as reported by ICMR and IIT Bombay.)
A CAR-T package is not a single line item. Understanding the stages helps you see where the money goes — and why the total varies so much between patients. The cart therapy cost in India is driven most by the cell product and the length of the hospital stay.
| Stage | What it covers | Cost impact |
|---|---|---|
| Cell collection (apheresis) | Collecting your own T-cells from the blood | Moderate; part of the package |
| Manufacturing the cells | Genetic re-engineering & growing the CAR T-cells in a specialised lab | Largest single component |
| Conditioning chemotherapy | Short chemotherapy to prepare the body before infusion | Moderate |
| Infusion & hospital stay | The infusion plus inpatient monitoring | High & variable — depends on length of stay |
| Managing side effects | Treating cytokine release syndrome / neurological effects, possible ICU care | Highly variable — the biggest wildcard |
| Pre-treatment work-up | PET-CT, biopsy, blood tests (usually billed separately) | Separate from the CAR-T package |
Figures and inclusions vary by individual, product and centre; this table is a general guide, not a quote. Ask for a written, itemised estimate before committing. Related costs: PET-CT scan cost for lymphoma and what affects chemotherapy cost.
A number this large deserves honest, unbiased guidance — not a sales pitch. Here is how CION approaches it.
CAR-T is for selected relapsed or refractory lymphomas. Our team and tumour board assess eligibility against NCCN and ESMO guidance first, so you are not steered toward a ₹40–60 lakh option when a lower-cost, equally appropriate path exists.
CION does not manufacture or infuse CAR T-cells. We coordinate the pathway through an accredited partner facility equipped for cell therapy, and manage your work-up, referral and follow-up care directly.
You receive an itemised estimate showing what is and isn't included, so there are no surprises. We also help you understand insurance and cashless cover before you decide.
We lay CAR-T alongside other options — immunochemotherapy, a stem cell transplant, or ongoing standard care — so you can weigh cost against benefit for your specific situation.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Wondering whether CAR T-cell therapy is right for your lymphoma — and what it would actually cost? CION's team will review your case and give you honest, itemised guidance.
CAR-T stands for chimeric antigen receptor T-cell therapy. In simple terms, your body's own immune cells are turned into a targeted therapy against your lymphoma. The steps are:
CAR-T is generally considered for specific B-cell lymphomas that have relapsed or not responded after two or more prior lines of treatment. It is not a first-line therapy. Because it is powerful, high-cost and carries real risks, careful eligibility assessment matters — that is the focus of our CAR T-cell therapy for lymphoma page.
For most patients, CAR-T is not the relevant number to focus on. It sits at the top of the cost ladder and is reserved for selected relapsed or refractory cases. Putting it in context:
Most people with lymphoma are treated first with chemotherapy combined with an anti-CD20 monoclonal antibody (an immunotherapy), sometimes with radiation. This is far less costly than CAR-T and cures or controls the disease in the majority of cases. See the full lymphoma treatment cost in Hyderabad and immunotherapy (antibody) cost.
For some relapsed lymphomas, a stem cell transplant is considered before or instead of CAR-T. It typically costs less than CAR-T and — like CAR-T — is coordinated through an accredited partner facility, not delivered in-house.
Published series report Hodgkin lymphoma survival of roughly 80–90% and diffuse large B-cell lymphoma survival of about 60–70% with standard treatment (figures per NCCN and ESMO-referenced literature; outcomes vary by individual, subtype and stage). Because standard care already works well for most people, CAR-T's high cost is only justified in specific situations — which is exactly what a second opinion can clarify.
The most common side effect of CAR T-cell therapy is cytokine release syndrome — an intense immune reaction that can cause fever, low blood pressure and breathing difficulty, and may need intensive care. This is a major reason CAR-T is delivered only at accredited centres equipped to manage it, and why the length of hospital stay is one of the biggest drivers of the final cost. (Source: NCCN and ESMO clinical guidance on CAR T-cell therapy.)
Because the sums are large, how you fund CAR-T matters as much as the sticker price. A few honest pointers:
Choosing where to have treatment matters too — see what makes a good lymphoma treatment centre. And for treatment closer to home, our lymphoma treatment in Hyderabad and best lymphoma hospital in Hyderabad pages explain what CION delivers directly.
Given the cost and complexity, a second opinion is especially worthwhile before proceeding with CAR-T. It is valuable when:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, not billing — with transparent costs explained up front. Get cost estimation or call 18002028726, and see the best lymphoma doctors in Hyderabad.
Get a free written second opinion from CION's lymphoma team — we'll confirm whether CAR T-cell therapy is genuinely indicated and give you a clear, itemised cost picture.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.For an Indian-manufactured CAR T-cell therapy, the cell product alone is typically in the range of about ₹30–45 lakh, and the total treatment package — including hospital admission, the conditioning step, monitoring for side effects and intensive-care backup — commonly runs to roughly ₹40–60 lakh. Imported products cost substantially more. These are indicative figures only; the actual car-t price for lymphoma depends on the exact product, the treating centre, the length of hospital stay and how complications are managed. CION does not manufacture or infuse CAR T-cells in-house; we coordinate the pathway through an accredited partner facility and give you a written, itemised estimate before you commit. Request a cost estimation for your specific situation.
CAR T-cell therapy is a personalised, one-time cellular treatment. Your own T-cells are collected, genetically re-engineered in a specialised laboratory to recognise a marker on the lymphoma cells (such as CD19), grown in large numbers and then infused back. That manufacturing is highly individualised and cannot be mass-produced, which is the single biggest driver of cost. On top of the cell product, the price reflects the specialised hospital admission, the short chemotherapy that prepares the body, close monitoring for reactions like cytokine release syndrome, and intensive-care readiness. The high price is why eligibility is assessed carefully and why simpler, effective options are used first where appropriate.
A complete CAR-T package generally covers several stages: the collection of your T-cells (apheresis); the genetic manufacturing of the cell product; a short course of conditioning chemotherapy before infusion; the infusion itself; and — often the largest variable — the inpatient stay with monitoring and treatment for side effects. Cytokine release syndrome and neurological effects can require intensive care and supportive medicines, which is why hospital-stay length changes the total so much. Costs for the pre-treatment work-up, such as a PET-CT scan and biopsy, are usually separate. CION coordinates each stage with the partner facility and itemises what is and isn't included in your written estimate.
Coverage is still evolving. Some private health insurance policies now cover cellular therapies, but limits, waiting periods and pre-authorisation rules vary widely, so it is essential to confirm the exact terms with your insurer in writing before proceeding. Government schemes such as Telangana's Aarogyasri and Andhra Pradesh's NTR Vaidya Seva cover many conventional lymphoma treatments, but high-cost cellular therapy is not routinely included — check current scheme rules for your case. Our team can help you understand your insurance and cashless options and check Aarogyasri eligibility for the wider treatment pathway.
CAR T-cell therapy is generally considered for specific B-cell lymphomas that have come back or stopped responding after standard treatment — usually after two or more prior lines of therapy. It is not a first-line treatment and it is not right for everyone. Most people with lymphoma respond well to conventional treatment such as immunochemotherapy and, where needed, radiation, which cost far less. Eligibility for CAR T-cell therapy for lymphoma depends on the lymphoma subtype, marker expression such as CD19, prior treatments and your fitness. Decisions are made by a multidisciplinary tumour board, in line with NCCN and ESMO guidance, so you are not steered toward an expensive option you do not need.
CAR T-cell therapy is one of the most expensive options, and it is reserved for selected relapsed or refractory cases rather than used first. Standard immunochemotherapy for lymphoma is far less costly, and a stem cell transplant sits between the two. For most patients, the relevant comparison is with the full lymphoma treatment cost in Hyderabad, which is driven by chemotherapy cycles, antibody (immunotherapy) drugs, scans and hospital stay. Because CAR-T is used only when it is genuinely indicated, we always confirm whether a lower-cost, equally appropriate path exists first. See what affects chemotherapy cost.
No — CAR T-cell therapy is delivered through accredited partner facilities that are equipped for cell manufacturing, infusion and the intensive monitoring involved. CION's role is to coordinate the pathway: our haematology and oncology team confirms whether CAR-T is genuinely indicated for your lymphoma, arranges the pre-treatment work-up, refers you to a suitable accredited centre, and manages your care before and after the therapy. The chemotherapy, antibody (immunotherapy) treatment, biopsies, PET-CT interpretation, tumour-board review and survivorship follow-up are delivered by CION directly. This coordinated model means you get honest guidance on whether the cost is worthwhile for your situation. Get a second opinion before deciding.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.